Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, reviews emerging therapeutics being investigated for the prevention and treatment of Clostridioides difficile infection (CDI).
Emerging research on the prevention and treatment of Clostridioides difficile infection (CDI) shows exciting potential for improved patient care over the next 5 years, said Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital.
Transcript
Is there any emerging research you find noteworthy in the management of CDI and any gaps in knowledge that warrant further investigation, such as pediatric care?
I think a lot of these [therapies] have not been studied in pediatrics, and certainly, that is a huge gap. I think what's also exciting in this space is that Rebyota [fecal microbiota, live-jslm] is not the only LBT [live biotherapeutic] that has been being explored.
We know that Seres Therapeutics has their own capsule formulation that is being considered by the FDA right now for approval. There's also Vedanta Biosciences and Finch Therapeutics, which also have products in phase 3 clinical trials right now. I think this is an area that is rapidly expanding. So, overall, great for the field and great for patients, because there's going to be a lot of options to prevent recurrent C diff down the line.
Overall, I would just say C diff, again, continues to be a major health care issue. Again, it's still at epidemic levels. And so, I'm really thrilled to see that we're finally moving the needle forward with microbiome-based therapies. Antibiotics are not going anywhere; we're still using antibiotics to treat these [patients]. But I think this is a huge step forward, not only for the science in this field, but also for patient care. I think over the next 5 years, we're going to see major advancements, and I certainly hope at some point C diff is an issue that patients don't have to deal with anymore and we ultimately have a cure.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Areas of Unmet Need Continue to Burden Patients With gMG
April 2nd 2025Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.
Read More
AI in Health Care: Closing the Revenue Cycle Gap
April 1st 2025This commentary explores the current state, challenges, and potential of artificial intelligence (AI) in health care revenue cycle management, emphasizing collaboration, data standardization, and targeted implementation to enhance adoption.
Read More
Financial, Housing, Food Insecurity Raise Risk of Hospital, ED Visits
April 1st 2025Social determinants of health been long understood to influence health outcomes, and this new analysis explores more deeply the link between social risk exposure and rates of health care resource utilization.
Read More